{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:03:14Z","timestamp":1747184594417,"version":"3.40.5"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A remarkably high rate of post\u2010transplant relapse in patients with TP53\u2010mutated myelodysplastic syndrome\/acute myeloid leukemia (MDS\/AML) calls to question the utility of allogeneic stem cell transplant (HSCT). We, therefore, performed a retrospective analysis to compare the outcomes between HSCT (<jats:italic>N<\/jats:italic>\u2009=\u200938) versus non\u2010HSCT (<jats:italic>N<\/jats:italic>\u2009=\u200945) approaches. Patients in the HSCT cohort were younger (median age 63 vs. 72) while patients in the non\u2010HSCT cohort more commonly had complex karyotype with chromosome 17 aberrancy and 5q deletion (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.01). A total of 69 <jats:italic>TP53<\/jats:italic> variants including 64 pathogenic variants, and 5 variants of undetermined significance were detected. Nine patients (4 in HSCT and 5 in non\u2010HSCT) had multi\u2010hit <jats:italic>TP53<\/jats:italic> variants. After induction: 57.9% versus 56.6% in the HSCT versus non\u2010HSCT cohort achieved morphologic complete remission. Median time to HSCT was 6\u2009months and median follow\u2010up was 15.1\u2009months for HSCT and 5.7\u2009months for non\u2010HSCT. Median disease\u2010free survival (DFS) and overall survival (OS) were 11.7 and 15.9\u2009months for HSCT, and 4.1 and 5.7\u2009months for non\u2010HSCT cohorts, respectively. Non\u2010relapse mortality at 12\u2009months was 22% versus 44% for HSCT versus non\u2010HSCT. In the HSCT cohort, the rate of grade II\u2013IV acute and chronic graft\u2010versus\u2010host disease (GVHD) was 55% and 18%, respectively. None of the patients from the non\u2010HSCT cohort were alive while four patients from the HSCT cohort were alive, in remission, and without GVHD (GRFS) at the time of abstraction. Better treatment strategies for patients with TP53\u2010mutated MDS\/AML remain an area of unmet clinical need.<\/jats:p>","DOI":"10.1111\/ejh.14199","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T09:44:55Z","timestamp":1711014295000},"page":"16-23","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with <i>TP53<\/i> mutation; a referral center experience"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-7093","authenticated-orcid":false,"given":"Kittika","family":"Poonsombudlert","sequence":"first","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Mott","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benda","family":"Miller","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajwal","family":"Dhakal","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Snow","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hornberg","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratdanai","family":"Yodsuwan","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida","family":"Magalhaes\u2010Silverman","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grerk","family":"Sutamtewagul","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa Hospital and Clinics  Iowa City Iowa USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201008\u2010733196"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002140"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201004\u2010779405"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010022\u201000571\u20108"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.021"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010023\u201001847\u20107"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123210"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2016.10.002"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S265637"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.180"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100710\u20107"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.269134"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018604"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.004"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00181"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010022\u201001314\u20103"},{"issue":"15","key":"e_1_2_11_21_1","first-page":"1","article-title":"Magrolimab plus azacitidine versus azacitidine plus placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study","volume":"39","author":"Garcia\u2010Manero G","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167259"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010023\u201005812\u20103"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2032642"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.151"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03522-6"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073274818789355"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003120"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131530"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:05:00Z","timestamp":1717416300000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/ejh.14199"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14199","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"2024-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}